Finance

Lists
KYMR:NASDAQ
Kymera Therapeutics Inc
$127.57
+0.31%
(+0.40) 1D
$127.57
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYMR...
Open
$126.93
High
$129.78
Low
$124.90
Mkt. cap
10.89B
Avg. vol.
958.51K
Volume
808.72K
52-wk high
$142.92
52-wk low
$62.13
EPS
-$3.62
Beta
2.04
Shares outstanding
85.37M
No. of employees
285
Open
$126.93
High
$129.78
Low
$124.90
Mkt. cap
10.89B
Avg. vol.
958.51K
Volume
808.72K
52-wk high
$142.92
52-wk low
$62.13
EPS
-$3.62
Beta
2.04
Shares outstanding
85.37M
No. of employees
285
News stories
From web sources and news partners
About Kymera Therapeutics Inc
CEO-
Employees285
Founded2015
HeadquartersWatertown, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitekymeratx.com
Analyst ratings
Based on 15 analysts giving stock ratings to KYMR in the past 3 months
Strong buy
Buy
14
Hold
1
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for KYMR in the last 3 months.
Highest
Current $127.57
$180.00 (+41.10%)
Average
$147.67 (+15.76%)
Lowest
$116.00 (-9.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Nash
Canaccord Genuity
Buy
Reiterated
$129.00
+1.1%
11/03/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$140.00
+9.7%
11/02/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$139.00
+9%
11/01/2026
Eliana Merle
Barclays
Buy
Maintained
$170.00
+33.3%
11/02/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$150.00
+17.6%
10/30/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$150.00
+17.6%
10/30/2026
Brian Abrahams
RBC Capital
Hold
Reiterated
$116.00
-9.1%
10/29/2026
Geoff Meacham
Citi
Buy
Maintained
$150.00
+17.6%
10/29/2026
Derek Archila
Wells Fargo
Buy
Maintained
$151.00
+18.4%
10/29/2026
Thomas Deal
Raymond James
Buy
Reiterated
$144.00
+12.9%
10/29/2026
Seamus Fernandez
Guggenheim
Buy
Maintained
$170.00
+33.3%
10/28/2026
Unknown Analyst
Raymond James
Buy
Initiated
$140.00
+9.7%
10/08/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
$140.00
+9.7%
09/28/2026
Biren Amin
Piper Sandler
Buy
Maintained
$140.00
+9.7%
09/23/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$152.00
+19.2%
09/22/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$144.00
+12.9%
09/14/2026
Andy Chen
Wolfe Research
Buy
Upgraded
$180.00
+41.1%
09/10/2026
Bradley Canino
Guggenheim
Buy
Reiterated
$170.00
+33.3%
08/30/2026
David Dai
UBS
Buy
Maintained
$128.00
+0.3%
08/05/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$134.00
+5%
08/06/2026
David Hoang
Deutsche Bank
Hold
Initiated
$120.00
-5.9%
07/29/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$140.00
+9.7%
07/16/2026
Daniel Giraldo
Bank of America Securities
Buy
Reiterated
$125.00
-2%
06/29/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
$136.00
+6.6%
06/29/2026
Mayank Mamtani
B. Riley Securities
Buy
Reiterated
$155.00
+21.5%
06/29/2026
Unknown Analyst
B. Riley Securities
Buy
Maintained
$155.00
+21.5%
06/26/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
$116.00
-9.1%
06/26/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
05/05/2026
Kelly Shi
Jefferies
Buy
Initiated
$110.00
-13.8%
03/15/2026
Faisal Khurshid
Jefferies
Buy
Initiated
$110.00
-13.8%
03/15/2026
Sudan Loganathan
Stephens
Buy
Maintained
$100.00
-21.6%
03/02/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$120.00
-5.9%
02/27/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
2.87M
34.36M
65.00M
-
Cost of goods sold
83.83M
98.16M
119.48M
128.51M
Cost of revenue
83.83M
98.16M
119.48M
128.51M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.94M
20.36M
21.13M
18.72M
Operating expense
16.94M
20.36M
21.13M
18.72M
Total operating expenses
100.77M
118.52M
140.61M
147.23M
Operating income
-97.90M
-84.15M
-75.61M
-147.23M
Other non operating income
-
5.00K
-25.00K
-15.00K
EBT including unusual items
-86.98M
-69.23M
-61.21M
-132.00M
EBT excluding unusual items
-86.98M
-69.23M
-61.21M
-132.00M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-86.98M
-69.23M
-61.21M
-132.00M
Net profit margin
-3,030.70%
-201.47%
-94.17%
-
Earnings per share
-0.98
-0.71
-0.62
-1.32
Interest and investment income
11.00M
14.98M
14.48M
15.30M
Interest expense
-90.00K
-66.00K
-56.00K
-47.00K
Net interest expenses
10.92M
14.92M
14.42M
15.25M
Depreciation and amortization charges
-
-
-
-
EBITDA
-97.46M
-82.13M
-74.48M
-144.31M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps